At the news
? BEARISHIMPACT 5/10 6-K filed Jun 26, 2026 at 11:59 ET
Dr. Reddy's received a Form 483 with seven observations from the USFDA following a Pre-License Inspection at its biologics manufacturing facility in Bachupally, Hyderabad (June 16-25, 2026). The company will respond within the stipulated timeline, but the observations raise compliance concerns that could delay future product approvals. This follows prior inspection-related disclosures in 2023 and 2025, suggesting ongoing regulatory scrutiny.
- USFDA completed a Pre-License Inspection (PLI) at Dr. Reddy's biologics facility in Bachupally, Hyderabad, from June 16 to June 25, 2026.
- The company was issued a Form 483 with seven observations, which it will address within the stipulated timeline.
- The filing references earlier inspection disclosures on October 12, 2023 and September 13, 2025, indicating a history of regulatory attention at this site.
- No financial impact, warning letter, or product-specific impact is disclosed in the filing.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access